Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Convalescent Plasma Therapy - Zurich Protocol (CPT-ZHP)

27 april 2021 uppdaterad av: University of Zurich

A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy

This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT) obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection and administered to patients who are infected with the new coronavirus and present dyspnea or a poor prognosis

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The outbreak of a new highly contagious and life-threatening infective disease was first reported in China in December 2019. Regardless of the undertaken containing measures, its spreading could not be effectively stopped and currently we are confronting the pandemic diffusion of a newly identified Coronavirus (SARS-CoV-2) (1). This causes a systemic disease, known as (Coronavirus Disease-19) COVID-19, characterised by a broad spectrum of clinical manifestations, including ineffective hyper-inflammation and severe pneumonia, with provisional epidemiologic data indicating a mortality rate of 0.1-15% (2). Do to the lack of vaccination, specific anti-virus sera or monoclonal antibodies, the therapeutic efforts to limit COVID-19 mostly rely on the empirical use of anti-viral drugs. Therefore, being the option of an active immunisation not available and because of the controversial efficacy of the available anti-viral therapies (3), we suggest the option of a passive immunisation for those patients who are infected with the new coronavirus and present dyspnea or a poor prognosis. The use of convalescent plasma, i.e. plasma obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection, could provide a rapid protection, limiting the observed evolution of COVID-19 towards life-threating manifestations (7-9).

When carried on according to standardised measures, the transfusion of plasma is highly safe (10-11) and we assume that products containing anti- SARS-CoV- 2 antibodies will provide the recipients a passive immunity through different mechanisms, including viral neutralisation, antibody-dependent cellular cytotoxicity and/or phagocytosis.

Studietyp

Interventionell

Inskrivning (Faktisk)

30

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Zürich, Schweiz, 8091
        • University Hospital Zurich

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

A) Proven Sars-CoV-2 by PCR and hospitalization for COVID-19 in combination with either (1) or (2):

  1. Age ≥50

    AND (at least one):

    • Pre-existing cardiovascular disease
    • Diabetic disease
    • Immunodeficiency/immunosuppression
    • Neoplastic disease
    • COPD or chronic liver disease or chronic renal failure
  2. Age ≥18

AND (at least one):

  • SpO2 ≤ 94% on room air or requiring supplemental oxygen at screening
  • Typical changes on chest x-ray and/or lung-CT scan
  • Immunosuppression or neoplastic disease

B) Informed Consent as documented by signature (Appendix Informed Consent Form) of the patient or, in case of inability, of the next relative/care-taking person. In the latter case, an independent doctor will also be involved and her/his signature will be required in order to enrol the patient.

Exclusion Criteria:

  1. Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product (FFP)
  2. Known IgA deficiency
  3. Cytokine Release Syndrome grade ≥3 (see score)*
  4. ARDS
  5. Patients already hospitalized in intensive care unit and/or already receiving mechanical ventilation
  6. Known or suspected non-compliance, drug or alcohol abuse
  7. Previous enrolment into the current study
  8. Enrolment of the investigator, his/her family members, employees and other dependent persons
  9. Women who are pregnant or breast feeding
  10. Intention to become pregnant during the course of the study
  11. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety of CPT applied to COVID-19 patients
Tidsram: clinical observation up to 48 hours after the last dose of plasma
Absence of clinical signs of Transfusion Related Lung Inflammation (TRALI) and/or allergic reactions and/or Transfusion Associated Circulatory Overload (TACO)
clinical observation up to 48 hours after the last dose of plasma
Safety of CPT applied to COVID-19 patients
Tidsram: 1 week (laboratory monitoring up to 7 days after the last administration of plasma)
Absence of laboratory signs of haemolytic reactions
1 week (laboratory monitoring up to 7 days after the last administration of plasma)
Improvement of respiratory frequency
Tidsram: 3 weeks after the last administration of plasma
Respiratory frequency will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of O2-saturation
Tidsram: 3 weeks after the last administration of plasma
O2-Saturation will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of Inflammatory markers (C Reactive Protein, CRP)
Tidsram: 3 weeks after the last administration of plasma
CRP will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of Inflammatory markers (Ferritin)
Tidsram: 3 weeks after the last administration of plasma
Ferritin will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of Inflammatory markers (IL-6)
Tidsram: 3 weeks after the last administration of plasma
IL-6 will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of coagulation-markers (D-dimer)
Tidsram: 3 weeks after the last administration of plasma
D-Dimer will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of coagulation-markers (Fibrinogen)
Tidsram: 3 weeks after the last administration of plasma
Fibrinogen will be measured at each study visit
3 weeks after the last administration of plasma
Improvement of coagulation-markers (LDH)
Tidsram: 3 weeks after the last administration of plasma
LDH will be measured at each study visit
3 weeks after the last administration of plasma
Prevention of ICU-admission
Tidsram: 3 weeks after the last administration of plasma
clinical conditions will be assessed throughout the study
3 weeks after the last administration of plasma

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Characterisation of virus reaction to plasma Therapy
Tidsram: 10 Weeks
Measurement of viral load after plasma therapy
10 Weeks
Characterisation of the dynamic of humoral response after therapy
Tidsram: 10 Weeks
Measurement of antibody-titres after plasma therapy
10 Weeks
Better characterize the the in-vivo anti-virus humoral response against SARS-CoV-2.
Tidsram: 10 Weeks
Performance of neutralisation assay after administration of plasma
10 Weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Markus Manz, Professor, University of Zurich

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 april 2020

Primärt slutförande (Faktisk)

30 november 2020

Avslutad studie (Faktisk)

30 mars 2021

Studieregistreringsdatum

Först inskickad

8 april 2021

Först inskickad som uppfyllde QC-kriterierna

27 april 2021

Första postat (Faktisk)

3 maj 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 maj 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 april 2021

Senast verifierad

1 april 2021

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2020-00787

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera